New initiatives to accelerate the development and manufacture of new medicines that could have real benefits to patients will share almost £50 million. The funding is from Innovate UK under the Industrial Strategy Challenge Fund.
This is the leading edge healthcare challenge, which supports UK businesses and researchers to develop and manufacture new medicines and vaccines, as well as digital health products and medical technologies. A total of £181 million will be invested over 4 years.
The project will look at the manufacturing process for the adeno-associated virus. This virus infects humans but is not known to cause disease, making it a good candidate for gene therapies. It should help to deliver new treatments more quickly and efficiently.
New digital healthcare solutions
Innovate UK will also invest £8 million in 52 projects through the digital health technology catalyst, which aims to improve patient outcomes, access to healthcare and service delivery and treatments.
Digital therapeutics start-up Neurofenix will partner with Brunel University London to develop Gameball, an affordable and enjoyable rehabilitation programme for patients with neurological impairment, which includes people that have suffered strokes.
Patients will use a hand-controller and connected software to take part in digital games. It will provide upper-limb training to help patients regain mobility, an online community of support, as well as analytics on performance.
£21 million will go towards setting up a network of 3 advanced therapies treatment centres that span the UK.
The centres will be alliances between the north of England and Scotland, and the Midlands and Wales, with the final site being based in Manchester.
This is a joint collaboration between hospitals, therapeutics development businesses and the supply chain. It should advance the use of pioneering cell and gene therapies with a large number of patients.
Building the UK’s capacity
Finally, a further £5.6 million will go to the manufacture and production of viral vectors.
Viral vectors are important to advanced therapies as the carrier of gene therapy treatments. However, there is a shortage of capacity for making viral vectors in the UK.
The projects funded under this competition will expand commercial capacity in the UK and increase the ability to produce viral vectors to be used in advanced therapy medicinal products.
Work will be conducted at 2 locations at Oxford and Keele, Staffordshire.